The board of directors of the Company (the “Board”) is pleased to announce that the on-site work of phase III clinical trials for 13-valent pneumonia conjugate vaccine, iterative serum-free rabies vaccine and 23-valent pneumonia polysaccharide vaccine developed by the Group has been completed. The Group is making preparations for the application for marketing of new drugs, and intends to complete the application for marketing in 2024. In addition, the Group has completed the construction of production workshops for the above three vaccines, and completed the production of samples for phase III clinical trials in the completed production workshops.